The pharmaceutical industry has witnessed a immense growth through the last decade. Several pharmaceutical companies have built a stronghold in the space but very few have managed to meet the needs of the industry. “Most Indian pharmaceutical companies opted the for Forward integration and front end marketing. However, there was a need for a trustworthy and dependable API manufacturer who could meet stringent quality and regulatory requirements,” says J. Rajender Rao, Chairman and MD, RA Chem Pharma Ltd. To mitigate these needs Rajender along with Sirish Kumar, Ravi K. Yerra and B. Srinivasa Reddy founded RA Chem Pharma in 2003.
Headquartered in Hyderabad, the company is balanced with collective strength and judgement of four leaders who bring experience from different domains.. They drive the company to bring fruitful successes by serving in three business verticals such as, API & Intermediates, Formulations and Clinical Research. All of these three facilities have international accreditations and approvals such as, USFDA, UKMHRA, EMEA (Europe) COFEPRIS (Mexico), KFDA (Korea) and they also have world class facilities in terms of size of operations and scale of business. “Each of our three facilities are standalone profitable business units run by independent professionals. Interestingly when an integrated support is required then either two of them or many times all three units collaborate independently to deliver the final product,” says Sirish. Naturally, in the last thirteen years,
RA Chem has managed to develop strong bonds with almost all top pharmaceutical companies in India and abroad either as a standalone business vertical or as an integrated service provider.
“We realized that there were several niche business opportunities in terms of products, markets and services which the global clients were looking for from India and China. Unfortunately the manufacturing sector is unable to address the same,” adds Sirish. “Understanding the needs of the global business, RA Chem takes care of the most important aspects of its servicing domain such as, end to end support, timely execution of projects in a cost effective manner along with proactive project management and quick decision making have aided in successfully completion of several projects in time,” explains Sirish.
RA has managed to develop strong bonds with almost all top pharmaceutical companies in India and abroad
From being a contract manufacturer and major presence in semi-regulatory sectors the company has succeeded in entering regulatory and developed markets for all the three verticals of business.
The company has put a lot of effort during the past few years to create a successful and meaningful partnership models with the regional players as well as with the global Bigwigs. These models help in strengthening the top and the bottom line while continuing the focus on the approach of focusing on the niche segment in areas of products, partners and markets. Presently, the company is exporting to more than 40 countries and works closely with innovators as well as generic players in national and global platforms. RA’s initial plan was to create an integrated model within a time span of fifteen years which it successfully achieved in less than ten years. With its collective experience of over 50 years RA has realized that the industry still had certain unmet demands that can be addressed by implementing each other’s strength and efforts.